You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
AstraZeneca
Moodys
Medtronic
Harvard Business School

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

Us Pharm Holdings Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for US PHARM HOLDINGS, and what generic and branded alternatives to US PHARM HOLDINGS drugs are available?

US PHARM HOLDINGS has ten approved drugs.



Summary for Us Pharm Holdings
US Patents:0
Tradenames:10
Ingredients:8
NDAs:10

Drugs and US Patents for Us Pharm Holdings

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 DISCN Yes No   Start Trial   Start Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 DISCN Yes No   Start Trial   Start Trial
Us Pharm Holdings CLAFORAN cefotaxime sodium INJECTABLE;INJECTION 050547-004 Dec 29, 1983 DISCN Yes No   Start Trial   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 AB RX Yes No   Start Trial   Start Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-003 Dec 11, 2001 DISCN No No   Start Trial   Start Trial
Us Pharm Holdings CLAFORAN cefotaxime sodium INJECTABLE;INJECTION 050547-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Us Pharm Holdings

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings TRENTAL pentoxifylline TABLET, EXTENDED RELEASE;ORAL 018631-001 Aug 30, 1984 4,189,469   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-006 Approved Prior to Jan 1, 1982 3,454,554   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 3,454,554   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 3,454,554   Start Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 4,906,755   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-007 Feb 11, 1982 3,454,698   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Moodys
Boehringer Ingelheim
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.